standing of the role rhey play in malig nam cransformation, have led to clinical studies evaluaring antigen-specific' cancer V;lccines chat target biologically relevant proteins. l This approach holds meoretic promise for potential eradicatio n of residual subclinical disease through active .
. . lmmuruzanon.
The HER2/neu prmem is a rumor anti gen. It consiscs of a large cysteine-rich extraCellular domain (EeD) which prob ably funccions in ligand binding, a shorr transmembrane domain, and a small cytoplasmic domain ,,:,iili tyrosine kinase a.crivity. In some nonna! adult tissue cells, me HER2/neu gene is present as a single capy.l Amplificacion of the gene or over e..xpressiol1 by posnranscriptiol1al medl al1isms leads W overexpression of the associated p[Qrein and, rhus, plays a role in malignanr transformarion by con rriburing to the uncontrolled growm of cancer cells. HER2/ neu overexpression has been described in a variety of dif ferenc tumor types, including breast, ovarian, non-small-ce!llung, renal cd!, prost<ue, pancreas, colon, gastric, salivary, bladder, and oral squamous cell carcino mas. HER2/neu overexpression, in gen eral, is regarded as a poor prognostic factor. In addition, HER21 neu overex pression appears w be a prediccive factor ror resistance m some chemomerapeucic agencs)-G Studies from our laboratory and others have demonstrated that: some patients with HER2!nro-over=pressing cancers have existent antibody and T-cell re sponses to the protein. Tables 2 and 3, respec tive!y. 'The components of rhe plan are designed ro answer me follo"'mg questions.
Is There Any Baseline Organ Damage Which Would Preclude-Enrollment:'
A hisrory and physical, complere blood coum and diffi:renci:al, blood urea nitrogen, se~ creatinine, alanine aminotransferase.
and tocal bilirubin are performed.
Does the Patient's Immu.ne System Function?
After informed consenr, delayed-type hypersensitivity (DTH) to seven common • An"gen-sp.,;iflc T,,,!! and annbody assays Vaccine Schedule
Is 
